Wednesday, June 03, 2020 8:30:26 AM
AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.
Full PR:
https://finance.yahoo.com/news/volition-files-patent-nu-q-123000672.html
Recent VNRX News
- Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems • PR Newswire (US) • 03/06/2026 01:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:32:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:32:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:32:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:31:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:31:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:30:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:30:29 PM
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution • PR Newswire (US) • 02/25/2026 01:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 10:15:32 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/20/2026 05:15:15 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/11/2026 10:05:44 PM
- Volition Announces the Appointment of New Distributor for Nu.Q® Discover • PR Newswire (US) • 02/10/2026 01:07:00 PM
- VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards • PR Newswire (US) • 02/09/2026 10:20:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 10:16:09 PM
- Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation • PR Newswire (US) • 02/04/2026 01:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:05:05 PM
- VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays • PR Newswire (US) • 01/30/2026 01:50:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
